Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM) FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory win, that position certainly isn't one of many

#SBFM Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea Sunshine Biopharma (NASDAQ:SBFM) announced Health Canada approval for Domperidone through its subsidiary Nora Pharma to treat nausea, vomiting and to enhance gastrointestinal motility, including use for chemotherapy-induced nausea.The approval enables commercialization in Canada and expands Sunshine's generics portfolio. Market data in the release cites global Domperidone sales of $1.36B (2025), North America ~39% share, and Canada ~17% of North America.

#SBFM Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

www.stocktitan.net/news/SBFM/sunshine-bioph...

Leading Indicators, Monday October 20, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Mon Oct 20th - #WRN #USAS #SLI #PMI #IE #BCV #SBFM #COOT #TARS #SWKH #SPRB #WOLF - More: crystalequityresearch.com/leading-indi... - #smallcap

Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline Sunshine Biopharma (NASDAQ:SBFM) announced the commercial launch of generic doxycycline in Canada on October 20, 2025, with nationwide availability to pharmacies, hospitals and healthcare providers.The product is supplied as 100 mg tablets, manufactured in compliance with Health Canada regulatory standards and described as therapeutically equivalent to the reference product. Distribution is underway through established pharmacy networks and hospital channels.Company commentary ties the launch to its anti-infective expansion and cites a broader North American segment inside a global doxycycline market valued at $729 million in 2024 and forecast to reach $1.2 billion by 2030 (CAGR 8.6%).

#SBFM Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline

www.stocktitan.net/news/SBFM/sunshine-bioph...

Trade Alerts, Tuesday October 14, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Tue Oct 14th - #SBFM #PMEC #NVA #GWAV #EDBL #DRDB #WKEY #ULBI #TVRD #SBLX #REKR #QRHC #MNTS #GURE #CASS #ALM #MCRP #TTI #CCRD #AKA - More: crystalequityresearch.com/trade-alerts... - #smallcap

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM) FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma (NASDAQ:SBFM) is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and cash quickly. A lean machine that builds speed-step by step-compounding every strategic win so that

#SBFM Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience Sunshine Biopharma (NASDAQ:SBFM) announced on October 14, 2025 that its Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.The Company said the $5 million position will be acquired over time via a regulated digital asset custodian or by buying an ETF or proxy stock, and that it may allocate additional funds to increase Bitcoin holdings in the future. Management framed the move as a hedge and a high-conviction asset to strengthen the company's financial foundation while continuing focus on its drug development pipeline, including antiviral small molecules and mRNA-based cancer therapies.

#SBFM Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections Sunshine Biopharma (NASDAQ:SBFM) and the University of Arizona announced a new series of orally active, non‑covalent PLpro protease inhibitors that show dose‑dependent antiviral activity in mice infected with SARS‑CoV‑2. The compounds are potent against the PLpro enzyme, exhibited dose‑dependent efficacy in cellular SARS‑CoV‑2 models, and displayed favorable pharmacokinetic profiles in mice, rats and dogs. The program follows an initial PLpro library published in August 2024 in Journal of Medicinal Chemistry. Ongoing work includes dose‑dependent efficacy analysis in infected mice and further preclinical evaluation.

#SBFM Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Launches Opioid Alternative in Billion-Dollar Pain Management Market Sunshine Biopharma expands into Canadian generic drug market with Gabapentin launch, targeting neuropathic pain treatment. See growth projections.

#SBFM Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Reports Double-Digit Growth: Q1 Revenue Jumps 18% as Pipeline Expands with 6 New Drugs Q1 revenues reach $8.9M amid expansion of drug portfolio. New CCO appointed to drive commercial strategy. Latest cancer treatment study shows promising results. Learn more.

#SBFM Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market Sunshine Biopharma (NASDAQ:SBFM) has announced the launch of generic Lurasidone through its Canadian subsidiary Nora Pharma. The drug, a generic version of Latuda®, is designed for treating schizophrenia and bipolar depression. Available in 20mg, 40mg, 60mg, and 80mg strengths, the medication comes in 30-tablet bottles. The global Lurasidone market, valued at $1.2 billion in 2024, is projected to reach $2.5 billion by 2033, growing at an 8.01% CAGR. While Canada represents 2.2% of the global pharmaceutical market, it ranks as the eighth-largest pharmaceutical market globally. The Canadian generic drugs market, currently at $9.4 billion, is expected to reach $19.2 billion by 2032.

#SBFM Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

www.stocktitan.net/news/SBFM/sunshine-bioph...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed Apr 2nd - #CORZ #WULF #BB #RKT #JYD #SBFM #WOLF #WKEY #NCNO #NGD #TRMD #STNE #SSYS #SPTN #RGTI #QBTS #NXE #CC #BORR #EWTX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

$2.46M Institutional Investment: Sunshine Biopharma Announces Strategic Direct Offering Institutional investors back Sunshine Biopharma with $2.46M direct offering at $2.07 per share. Includes warrant options. See complete financing terms.

#SBFM Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

www.stocktitan.net/news/SBFM/sunshine-bioph...

Revolutionary mRNA Treatment Succeeds Against Deadly Liver Cancer in Latest Trial Novel mRNA therapy demonstrates significant tumor reduction in liver cancer models. Two treatment versions show strong efficacy with good tolerability. Full analysis inside.

#SBFM Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Reports Record Revenue: 13 New Drugs and Cancer Treatment Breakthrough Revenue jumps 45% as Sunshine Biopharma launches 13 new drugs and advances cancer treatments. Key developments include Health Canada approval and breakthrough liver therapy.

#SBFM Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

www.stocktitan.net/news/SBFM/sunshine-bioph...

Major Antibiotics Deal: Sunshine Biopharma Expands Portfolio in Billion-Dollar Market Strategic acquisition grants rights to two antibiotics, expanding Sunshine's 70-drug portfolio. Set to capture share of Canada's $1.2B market. Full analysis inside.

#SBFM Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market Sunshine Biopharma (NASDAQ:SBFM) has announced that its Canadian subsidiary, Nora Pharma, has acquired rights to two gastrointestinal drugs in the Canadian market, with one already launched and the second planned for launch within 9 months.The first launched drug is Prucalopride, a generic version of Resotran®, available in 1mg and 2mg tablet strengths. The drug treats chronic idiopathic constipation in adult women when laxatives are ineffective by stimulating 5-HT4 receptors to enhance gastrointestinal motility.Both drugs target the chronic idiopathic constipation submarket within Canada's $200 million CAD gastrointestinal market. The sector is projected to grow at a 4.64% CAGR from 2024 to 2034, driven by increasing gastrointestinal disorder prevalence and treatment awareness.

#SBFM Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Launches Generic Mental Health Drug in Rapidly Growing Canadian Market Sunshine Biopharma expands portfolio with Olanzapine, targeting schizophrenia and bipolar disorder treatment in Canada's $9.4B generic drug market projected to double by 2032.

#SBFM Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma's Novel COVID-19 Oral Treatment Shows Breakthrough Antiviral Activity in Preclinical Study Promising preclinical results reveal Sunshine Biopharma's oral protease inhibitor effectively targets SARS-CoV-2 variants with favorable lung accumulation and safety profile.

#SBFM Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

#news #StockMarket #investing

www.stocktitan.net/news/SBFM/sunshine-bioph...

Sunshine Biopharma Launches Generic Allergy Drug in $1.3B Global Bilastine Market | SBFM Stock News Sunshine Biopharma expands its Canadian portfolio with Bilastine, a generic allergy medication, marking its fourth product launch this year in the growing generic drugs market.

#SBFM Sunshine Biopharma Launches a New Generic Prescription Drug

#news #StockMarket #stocks

www.stocktitan.net/news/SBFM/sunshine-bioph...

NEWS: ( NASDAQ: #SBFM ) Sunshine Biopharma Announces Breakthrough Research Results on the Company's K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

#StockMarket #News

Just In: ( NASDAQ: #SBFM ) Sunshine Biopharma Launches a New Generic Prescription Drug

#StockMarket #News

#SBFM Sunshine Biopharma Launches a New Generic Prescription Drug

www.stocktitan.net/news/SBFM/sunshine-bioph...

Breaking News: ( NASDAQ: #SBFM ) Sunshine Biopharma Launches Two New Generic Prescription Drugs

#StockMarket #News

JUST IN: ( NASDAQ: #SBFM ) Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%

#StockMarket #News

Northbound Train 707 pulling into Helensvale station with Husky plush looking at the train

Husky plush sitting at a table filled with sauces and fried onions and cups, ready for a BBQ

Husky plush looking at a piece of meat remaining on a plate

Treble leaning back on the tram with their eyes closed and Husky plush laying on them

Yesterday was a busy day!!!

Caught the train up to have lunch in Brissy with friends and wondering around town all arvo (sadly no BotC on sale) before heading to SBFM!

Had a lovely meet and then dinner before heading back, both exhausted after a 15hr day

#SBFM #TrebleFurDU